AKCEA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
AKCEA THERAPEUTICS INC. - More news...
AKCEA THERAPEUTICS INC. - More news...
- MERGER ALERT – AKCA, FEAC, and BLDR: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
- MERGER ALERT – AKCA, RST, and BLDR: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
- Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Treatment
- Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
- Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
- Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
- Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
- Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
- Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
- Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
- Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
- Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
- Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
- New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
- Akcea Retains Rights to AKCEA-APOCIII-LRx
- Akcea Therapeutics Announces New Appointments to its Board of Directors
- Akcea Announces Appointment of New Chief Operating Officer
- Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
- Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
- Akcea Therapeutics to Present at Upcoming Investor Conferences
- Akcea Reports Financial Results and Highlights for Third Quarter 2019
- Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
- Akcea Announces Appointment of New Chief Commercial Officer
- Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
- Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
- Akcea Announces CEO Transition and Elects Two New Board Members
- Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
- Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
- New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
- Akcea Reports Financial Results and Highlights for Second Quarter 2019
